| Sr. No. |
Particulars |
Quarter ended 30.06.2007
(Unaudited) |
Quarter ended
30.06.2006
(Unaudited) |
Year ended 31.03.2007 (Audited) |
| 1 |
Income from Operations |
2886.39 |
3142.15 |
12840.07 |
| 2 |
Other income |
1.82 |
- |
22.96 |
| |
Total |
2888.21 |
3142.15 |
12863.03 |
| 3 |
Total Expenditure |
2785.28 |
2773.07 |
12249.18 |
| |
a) (Increase) / Decrease in stock-in-trade |
35.63 |
(85.06) |
(85.28) |
| |
b) Consumption of Raw materials |
1871.13 |
2070.24 |
8364.74 |
| |
c) Staff Cost |
385.76 |
345.23 |
1519.87 |
| |
d) Other Expenditure |
492.76 |
442.66 |
2449.85 |
| |
Operating Profit/ (Loss) |
102.93 |
369.08 |
613.85 |
| 4 |
Interest |
242.50 |
5.71 |
528.31 |
| 5 |
Depreciation and Amortisation |
1229.48 |
1229.46 |
4905.80 |
| 6 |
Profit / (Loss) before Extraordinary Items |
(1369.05) |
(866.09) |
(4820.26) |
| 7 |
Extraordinary Items |
- |
- |
(8474.80) |
| 8 |
Profit / (Loss) after Extraordinary Items |
(1369.05) |
(866.09) |
(13295.06) |
| 9 |
Provision for FBT |
3.25 |
1.89 |
22.55 |
| 10 |
Deferred Tax Reversal |
- |
- |
(2,444.49) |
| 11 |
Net Profit /(Loss) |
(1372.30) |
(867.98) |
(15762.10) |
| 12 |
Paid-up equity share capital |
4371.15 |
4220.80 |
4220.80 |
| 13 |
Reserves excluding revaluation reserves |
|
|
43907.72 |
| 14 |
Earning Per Share (in Rs.) - |
|
|
|
| |
Basic & Diluted |
(0.64) |
(0.41) |
(7.50) |
| 15 |
Aggregate of Non-Promoter Shareholding |
|
|
|
| |
Number of Shares |
148225952 |
140708412 |
140708412 |
| |
Percentage of shareholding |
67.82% |
66.67% |
66.67% |
Notes:
- The above results were reviewed by the audit committee and subsequently have been taken on record by the Board of Directors in its meeting held on 17th July, 2007 and are subject to limited review by the statutory auditors.
- The Company is exclusively engaged in the Pharmaceutical Business segment. Capital employed as on 30th June, 2007 is Rs. 73751.52 Lacs.
- Pending settlement, interest of Rs. 342.64 has not been provided on fixed deposits & for non- CDR Banks/FI's having exposure of Rs. 2202.91 Lacs. Scheme of arrangement & compromise under Section 391 of Companies Act, 1956 is pending adjudication before Hon'ble Himachal Pradesh High Court at Shimla.
- As part of settlement under Corporate Debt Restructuring (CDR) Scheme, 75,17,540 Equity Shares of Rs.2/- each fully paid up were issued to Banks/FI's at a premium of Rs. 18/- per share during the quarter. Also 88,02,276 Preference shares of Rs.100/- each fully paid , have been issued at par, to Banks/FI's as a part of CDR package after getting Shareholder approval.
- During the Quarter, 4 shareholders' complaint were received and resolved.
- The comparative figures are regrouped and reclassified, wherever considered necessary.
|
| |
Place: New Delhi
Date: 17.07.2007 |
(Sushil Suri)
Chairman & Managing Director |
